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Abstract 
Objective: To investigate the association between antidepressant use in late gestation and 
postpartum haemorrhage (PPH). 
Design: Retrospective cohort study 
Setting: Tertiary teaching hospital in Adelaide, Australia 
Population: A total of 30,198 women delivering between 2002 and 2008 
Methods: Relative risks adjusted for maternal sociodemographics and comorbidities (aRRs) 
were calculated for PPH, comparing women with late-gestation exposure to antidepressants 
(n=558), women with a psychiatric illness but no antidepressant use (n=1,292), and women 
with neither antenatal exposures (n=28,348). Additional sensitivity analyses were 
undertaking examining associations with severe PPH, and postpartum anaemia. 
Main outcome measures: The primary outcome was PPH, defined as a recorded blood loss 
of ≥500mL for vaginal deliveries and ≥1000mL for caesarean sections. Secondary outcomes 
included severe PPH (≥1,000mL blood loss, irrespective of method of delivery), and the 
presence of postpartum anaemia (identified from hospital medical records). 
Results: Compared to unexposed controls, women exposed to antidepressants had an 
increased risk of PPH (aRR 1.53; 95% confidence interval 1.25-1.86), whereas no increased 
risk was observed for women with a psychiatric illness but no antidepressant use (aRR 1.04; 
0.89-1.23). In sensitivity analyses, late gestation antidepressant exposure was associated with 
increased risk of severe PPH (aRR 1.84; 1.39-2.44), as well as postpartum anaemia (aRR 
1.80; 1.46-2.22).  
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Conclusion: Exposure to antidepressants in late gestation was associated with a significantly 
increased risk of PPH. While potential confounding by unmeasured factors cannot be ruled 
out, these findings suggest a direct effect of antidepressant exposure on PPH.  
 
Key Words: Antidepressive agents; prenatal exposure; pregnancy; selective serotonin 
reuptake inhibitors; postpartum haemorrhage 
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Introduction: 
Internationally there has been a striking increase in the numbers of women exposed to 
antidepressants during pregnancy. In Denmark, prescribing of antidepressants during 
pregnancy increased from 0.2% to 3.2% from 1997 to 2010,1 a trend mirrored in other 
countries such as the United States, where use increased from 2% to 7.6% from 1996 to  
2005.2 Antidepressant use has been associated with a range of adverse pregnancy outcomes, 
including preterm birth, persistent pulmonary hypertension of the newborn, and poor neonatal 
adaptation.3-6 While some of these outcomes may be confounded by underlying maternal 
illness, there is a continual need to assess the benefits and safety of antidepressant use during 
pregnancy in an effort to guide and improve clinical care and health outcomes.  
In non-pregnant adults a number of, but not all, studies have demonstrated that 
antidepressant use is associated with increased risks of gastrointestinal, perioperative, and 
other bleeding events.7-11 This is thought to occur through an effect on the depletion of 
serotonin within platelets, with serotonin playing an important role in influencing the platelet 
– endothelial cell interaction, and platelet activation and aggregation.12 Evidence to date is 
equivocal in relation to antidepressant use near delivery and risk of postpartum haemorrhage 
(PPH), with four studies demonstrating inconsistent findings in relation to the use of all 
antidepressants combined13, or the use of serotonin and non-serotonin reuptake inhibitors 
investigated separately.14-16 In addition, major differences and limitations are evident in 
previous studies across key methodological aspects such as sample size, outcome definitions 
used, and adjustment for possible confounders.13, 15-17 Palmsten et al. provide the most 
extensive and compelling evidence regarding an increased risk of PPH following 
antidepressant use close to delivery.17 Among a cohort of more than 10,000 exposed 
pregnancies, the largest to date, use of serotonin reuptake inhibitors near delivery was 
associated with a 1.47-fold increased risk (95% confidence interval 1.33 to 1.62) of PPH and 
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use of non-serotonin reuptake inhibitors associated with a 1.39-fold increased risk (1.07 to 
1.81). As this study was undertaken among low income women enrolled in the US Medicaid 
program, the generalizability of these findings to other populations remains to be determined. 
In light of this and existing evidence, we sought to investigate the association between 
antidepressant use in late pregnancy and risk of primary PPH.  
Methods: 
Eligible Population 
We undertook a retrospective cohort study involving all births in the Children, Youth 
and Women’s Health Service (CYWHS) in South Australia between January 2002 and 
December 2008. Data were obtained from linkable routinely collected health administrative 
data within the Women’s and Children’s Hospital (WCH), which included the Perinatal 
Statistics Collection and Hospital Pharmacy Dispensing Records. Each individual’s unique 
hospital identifier number was used to link related health records. The eligible population 
consisted of 30,198 pregnancies from 24,266 women. 
Exposure 
The WCH pharmacy dispensing records were utilised to obtain data on women 
dispensed an antidepressant during pregnancy. . The hospital pharmacy dispensing records 
have previously been validated as an indicator of late gestation exposure to antidepressants 
during pregnancy,18 and have been utilised in research evaluating outcomes following 
antidepressant use in pregnancy 19, 20.  
Women with a reported psychiatric illness during pregnancy, as identified through the 
Perinatal Statistics Collection, but who were not dispensed an antidepressant, served as a 
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disease comparitor. The unexposed control group comprised of women who were not 
dispensed an antidepressant and had no reported psychiatric illness during pregnancy. 
Outcome 
The primary outcome measure was primary PPH, defined as a blood loss of ≥ 500mL 
following vaginal delivery and ≥ 1000 mL following a caesarean section. Secondary 
outcomes included severe PPH, defined as blood loss ≥ 1000mL within 24 hours of delivery, 
as well as postpartum anaemia.  
These outcomes were based on data routinely collected and recorded in the WCH 
Perinatal Statistics Collection. The Perinatal Statistics Collection involves the collection of 
data on the pregnancy and outcome of every live birth and late fetal death occurring at the 
WCH by a specially trained research midwife. Data are collected using a structured coding 
sheet, with data collected on    maternal illnesses (e.g. pre-existing hypertension or diabetes, 
epilepsy, asthma and psychiatric illness), lifestyle factors (e.g. smoking), obstetric history, 
pregnancy complications (e.g. gestational diabetes) and newborn characteristics (e.g. birth 
weight). The data collected for the Perinatal Statistics Collection are checked manually for 
completeness and data discrepancies and then go through a series of automated validation 
procedures during data entry. The information in the Perinatal Statistics Collection has been 
previously validated and has been shown to be very reliable when compared with hospital 
medical records.21 
Statistical Analysis 
We compared the risk for PPH or postpartum anaemia between women with exposure 
to either antidepressants or psychiatric illness without antidepressant use and the unexposed 
group using relative risks and risk differences and their corresponding 95% confidence 
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intervals from generalised linear models (Poisson distribution). Models were adjusted for 
potential confounders and robust variances were used to account for correlations among 
multiple pregnancies in the same woman. Outcomes were stratified according to method of 
delivery to evaluate the potential for effect modification.  To support the validity of our 
outcome definition, we also assessed the association between well-established risk factors for 
PPH and occurrence of PPH. Finally, we examined differences in the prevalence of known 
risk factors for PPH across each of the exposure groups to identify potential mediators. All 
analyses were performed using Stata 12.1 (Stata, College Station, TX, USA). 
Results  
Of the women eligible to participate in this study (n=30,198), 558 were dispensed an 
antidepressant (exposed), 1,292 had a reported psychiatric illness but were not dispensed an 
antidepressant (non-medicated psychiatric illness) and 28,348 did not have a reported 
psychiatric illness and were not dispensed an antidepressant during pregnancy (unexposed). 
All women were dispensed only one type of antidepressant (in order of frequency; SSRIs: 
sertraline [n=194], citalopram [n=133], paroxetine [n=57], fluoxetine [n=27], fluvoxamine 
[n=17], escitalopram [n=7]; SNRIs: venlafaxine [n=64]); TCAs: amitriptyline [n=29], 
dothiepin [n=10], imipramine [n=3], clomipramine [n=1], nortriptyline [n=1], doxepin [n=1]; 
other antidepressants: mirtazapine [n=13], moclobemide [n=1]). The majority of women 
dispensed an antidepressant had a reported psychiatric illness (n=554), with the remainder 
potentially using antidepressants for an alternative indication such as neuropathic pain.  
Compared with unexposed women, more women in the antidepressant exposed group 
were older, multiparous, smokers, Caucasian, using other psychotropic medications during 
pregnancy, and had asthma, pre-existing diabetes or hypertension, and a previous LSCS 
(Table 1). In contrast, compared with women with a psychiatric illness but no antidepressant 
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use, more women in the antidepressant exposed group were older, of higher socioeconomic 
status, non-smokers, multiparous, using other psychotropic medications during pregnancy, 
and had pre-existing diabetes or hypertension.  
The overall risk of PPH was 11% among unexposed women, 11% among women with 
a psychiatric illness but no antidepressant use, and 16% among women exposed to 
antidepressants (Table 1). The risk of severe PPH was 5% among unexposed women, 5% 
among women with a psychiatric illness but no antidepressant use, and 9% among women 
exposed to antidepressants. Compared with women without each predisposing factor, women 
with placenta praevia (RR 3.25; 2.85 to 3.71), prolonged labour (RR 1.42; 1.25 to 1.85), 
hypertensive disorders of pregnancy (RR 1.23; 1.11 to 1.35), and assisted vaginal delivery 
(RR 1.60; 1.47 to 1.73) had an increased risk of PPH. Following adjustment for potential 
confounders, antidepressant use in late pregnancy was associated with a significantly 
increased risk of PPH (aRR 1.53; 1.25 to 1.86), with no increased risk observed for women 
with a psychiatric illness but no antidepressant use (aRR 1.04; 0.89 to 1.23) (Table 2). This 
risk associated with antidepressant use remained significant irrespective of method of 
delivery. Additional adjustment for maternal BMI, which was recorded in approximately two 
thirds of pregnancies, increased the risk estimate slightly (aRR 1.66: 1.32 to 2.07). 
The risk of severe PPH following antidepressant use in late pregnancy was even 
higher (aRR 1.84; 1.39 to 2.44), with no increased risk observed for women with a 
psychiatric illness but no antidepressant use (aRR 1.10; 0.85 to 1.42) (Table 3). This 
associated risk for antidepressant use remained significant irrespective of method of delivery. 
In absolute terms, women with late gestation antidepressant exposure had an adjusted excess 
risk of 5.8% (2.5% to 9.1%) for any PPH, with a number needed to harm of 17; the figure for 
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adjusted excess risk of severe PPH was 3.9% (1.5% to 6.1%), with a number needed to harm 
of 26.  
The prevalence of measured risk factors for PPH were compared according to 
maternal exposure status associated with an increased risk of PPH according to exposure 
status, with none observed to be substantial mediators of the current associations between 
antidepressant use and PPH (Table S1 S2). 
In order to further explore the relationship between antidepressant use and PPH, we 
also investigated the association with the identification of postpartum anaemia. In accordance 
with the observed increased risk of PPH, use of antidepressants in late pregnancy was 
associated with a significantly increased risk of postpartum anaemia (aRR 1.80; 1,46 to 2.22) 
(Table 4). No increased risk was observed among women with a psychiatric illness but no 
antidepressant use (aRR 1.01; 0.83, 1.22). 
Discussion 
Main findings 
Antidepressant use in late gestation was associated with about a 1.5-fold increase in 
risk of PPH and 6% excess risk. This increased risk was observed to be independent of the 
mode of delivery and could not be explained by an increased risk of known measured risk 
factors for PPH among antidepressant users.  
Strengths and Limitations 
Strengths of this study included the inclusion of a control group of women with non-
medicated psychiatric illness and in contrast to previous studies, we were able to adjust for a 
range of behavioural factors including the use of tobacco, alcohol and illicit drugs, which are 
often inadequately collected in data on healthcare use. 
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This study is subject to a number of limitations. While we adjusted for a number of 
measured potential confounders with standard multivariable regression which did not affect 
the results, the potential for unmeasured confounding remains. We did not have sufficient 
data on some known risk factors for PPH, such as use of oxytocin in delivery. The inclusion 
of a control group of women with an identified psychiatric illness, but who were not taking 
antidepressants in late pregnancy, failed to demonstrate any increased risk of PPH associated 
with underlying maternal illness, a finding consistent across previous studies.15, 17 No 
information, however, was available on the severity of the psychiatric illness and it remains 
possible that women continuing to take antidepressants into late pregnancy have more severe 
underlying illness and that unmeasured factors that are associated with the severity of the 
illness could have confounded the results. While the hospital pharmacy dispensing records 
utilised in this study are an efficient alternative to paper-based medical records in 
determining late gestation exposure to SSRIs, they underestimate exposure by approximately 
25%.18 As a result of this underestimation it is possible that some women in the control 
groups were actually exposed to an antidepressant in late gestation. Based on previous 
research, we are aware that this form of misclassification bias due to incomplete 
ascertainment of antidepressant use in late gestation is unlikely to have substantially biased 
the risk estimates, with slight attenuation towards the null.22, 23 We did not have adequate 
power to examine the associations according to the individual type of antidepressant, their 
dose, or between antidepressants and severe PPH leading to a blood transfusion or mortality. 
Outcome misclassification is another source of bias, which would likely result in an 
underestimation of a true association. While estimating blood loss is notoriously difficult and 
prone to inaccuracy, given the recording of blood loss is likely to be independent of 
antidepressant exposure, this is unlikely to explain the observed associations. Moreover, the 
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Our findings our very similar to those reported by Palmsten et al., who, through a 
large data-linkage study of more than 10,000 women exposed to antidepressants in the US, 
observed that use of serotonin reuptake inhibitors near delivery was associated with a 1.47-
fold increased risk (95% CI 1.33 to 1.62) of PPH17  Similarly, a large Swedish data-linkage 
study undertaken by Reis et al. identified a very similar 1.45-fold increased risk for PPH 
(95% CI 1.27–1.65). In this study, antidepressant use was combined into a single group and 
examined during late pregnancy.13 Overall, these findings are slightly higher than those 
observed in a case-control study undertaken by Salkeld et al., who investigated outcomes 
separately for SSRI (aOR 1.33; 0.94, 1.89) and non-SSRI antidepressants (aOR 1.29; 0.58, 
2.84).16 This study, however, suffered from a small number of exposed cases, limiting the 
precision of the identified risk estimates. All three of these studies utilised standardised ICD-
9 codes for the identification of PPH.13, 16, 17 In contrast to these and our study, Lupattelli et 
al. investigated outcomes among women taking antidepressants within the Norwegian Birth 
Cohort Study.15 They observed an increased risk among women exposed to TCAs and other 
antidepressants in late pregnancy (aOR 3.75; 1.09, 12.94), but not following exposure to 
SSRIs or SNRIs combined (aOR 0.97; 0.57, 1.65). A notable difference did exist in their 
definition of PPH, however, defined as a blood loss greater than 500mL irrespective of the 
method of delivery, deviating from existing guidelines25  
While Lupattelli et al. is the only study to have directly measured and adjusted for 
maternal depressive symptoms, the presence of depressive symptoms themselves in the 
absence of antidepressant exposure did not appear to be associated with any appreciable risk 
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of PPH (aOR 1.14; 0.97, 1.34).15 Despite the absence of direct measures of depressive 
symptoms, Palmsten et al. restricted their analyses to women with diagnoses for mood or 
anxiety disorders in the 1-5 months prior to delivery, whilst also adjusting for a number of 
confounders likely associated with severity of underlying maternal illness.17 Similarly, we 
attempted to control for underlying maternal illness by including a control group of women 
with a non-medicated psychiatric illness, with no increased risk of PPH observed in this 
group.  
While the exact mechanism linking the use of antidepressants with postpartum  
haemorrhage and other bleeding related events remains uncertain, it is thought that this may 
occur, at least in part, though alterations in platelet function.26, 27 Serotonin has been 
demonstrated to play an important role in potentiating platelet aggregation,26 with platelets 
reliant on serotonin transporters for the uptake of serotonin from the circulation as they are 
not capable of synthesising serotonin themselves.27 Administration of antidepressants that 
block the activity of the serotonin transporter lead to a depletion of platelet serotonin and 
interfere with the serotonin-dependant intracellular signalling pathway that facilitates platelet 
activation in conjunction with other cofactors. Risk of bleeding is unlikely to be restricted to 
the use of serotonin reuptake inhibitors, as the administration of 5-HT2A receptor antagonists, 
which represents a key mechanism of action of some antidepressants, is also associated with 
a decrease in platelet response and aggregation.28 Of additional interest is the role of the 
vesicular monoamine transporter (VMAT) within the platelet, which is involved in 
transporting serotonin across the dense granule membrane and vesicular storage. This raises 
the possibility that other antidepressants such as bupropion, which are thought to have 
indirect serotonergic activity through alterations in the regulation of the vesicular monoamine 
transporter,29 may also have an effect on intracellular serotonin concentrations and therefore 
platelet function.  
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This study is the first to report an association between late gestation exposure to 
antidepressants and risk of PPH in an Australian population. This increased risk was observed 
regardless of mode of delivery, was independent of underlying maternal illness, and could not 
be explained by an increased risk of identified risk factors for PPH among antidepressant 
users. Such increases in risk were similar in magnitude of those previously reported from 
Canadian, Swedish and US populations.13, 16, 17 As it is not possible to rule out residual 
confounding, further studies that account for clinical measures of severity of depression and 
behavioural factors associated with antidepressant use in late gestation are still required. If 
assumed causal, this represents just one component of the overall factors that should be 
considered in evaluating the benefits and risks associated with antidepressant use. While 
women and their physicians should be aware of the potential risks of PPH when making 
treatment decisions near the end of pregnancy, caution is advised against the routine cessation 
of antidepressants in late gestation until further research regarding optimal management 
strategies are available.  
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  No. (%)†  
Year of Delivery    
2002-2004 236 (42.3) 457 (35.4) 10834 (38.2) 
2005-2006 144 (25.8) 436 (33.8) 8298 (29.3) 
2007-2008 178 (31.9) 399 (31.0) 9216 (32.5) 
Age,     
< 20 27 (4.8) 100 (7.7) 1,432 (5.1) 
≥ 20-25 88 (15.8) 281 (21.8) 4,811 (17.0) 
≥ 25-30 141 (25.3) 352 (27.2) 8,160 (28.8) 
≥ 30-35 180 (32.3) 328 (25.4) 8,540 (30.1) 
≥ 35 122 (21.9) 231 (17.9) 5,405 (19.1) 
Socioeconomic Status    
1 (Lowest) 149 (26.8) 342 (26.5) 6,322 (22.4) 
2 104 (18.7) 225 (17.4) 5,699 (20.2) 
3 91 (16.3) 261 (20.2) 5,236 (18.5) 
4 104 (18.7) 233 (18.1) 5,601 (19.8) 
5 (Highest) 109 (19.6) 229 (17.8) 5,403 (19.1) 
Smoking Status    
Non-Smoker 352 (64.2) 698 (54.8) 21,667 (78.9) 
Quit 18 (3.3) 79 (6.2) 1,121 (4.1) 
Smoker 178 (32.5) 497 (39.0) 4,681 (17.0) 
Race    
Caucasian 509 (91.2) 1,139 (88.2) 21,990 (77.6) 
Asian 37 (6.6) 113 (8.8) 2,916 (10.3) 
Other 12 (2.2) 40 (3.1) 3,431 (12.1) 
Parity ≥ 1 360 (64.8) 721 (55.9) 15,706 (55.4) 
Plurality > 1 18 (3.2) 29 (2.2) 777 (2.7) 
Psychotropic Medication 
Use 
91 (16.3) 98 (7.6) 356 (1.3) 
Pre-Existing Medical 
Conditions 
   
Coagulopathies 6 (1.1) 6 (0.5) 102 (0.4) 
Diabetes 16 (2.9) 15 (1.2) 244 (0.9) 
Hypertension 20 (2.6) 21 (1.6) 363 (1.3) 
Asthma 94 (16.9) 217 (16.8) 2,029 (7.2) 
Previous Obstetric History    
Caesarean Section 115 (20.6) 188 (14.6) 4,088 (14.4) 
Antepartum haemorrhage 7 (1.3) 30 (2.3) 324 (1.1) 
Postpartum haemorrhage 25 (4.5) 44 (3.4) 895 (3.2) 
† percentages calculated from non-missing values 
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Table 2. Relative risks (RR) and 95% confidence intervals (CI) comparing risk for primary postpartum haemorrhage (≥ 500 mL following 
vaginal delivery or ≥ 1000 mL following caesarean section) according to exposure to antidepressants, psychiatric illness, or neither during 
pregnancy 
 Total No (%) of 
women with 
PPH 
Unadjusted Adjusted for delivery year* Fully Adjusted† 
   RR RR 95% CI RR 95% CI 
Any Type of Delivery        
Antidepressants 558 91 (16.3) 1.48 1.47 1.22, 1.78 1.53 1.25, 1.86 
Psychiatric Illness 1292 139 (10.8) 0.98 0.99 0.84, 1.16 1.04 0.89, 1.23 
Unexposed 28348 3128 (11.0) Reference Reference  Reference  
Caesarean Section        
Antidepressants 210 29 (13.8) 1.68 1.68 1.19, 2.37 1.70 1.20, 2.40 
Psychiatric Illness 391 34 (8.7) 1.06 1.08 0.78, 1.51 1.20 0.86, 1.67 
Unexposed 7 997 657 (8.2) Reference Reference  Reference  
Vaginal Delivery        
Antidepressants 348 62 (17.8) 1.47 1.45 1.16, 1.82 1.47 1.16, 1.86 
Psychiatric Illness 901 105 (11.7) 0.96 0.97 0.81, 1.17 1.01 0.84, 1.22 
Unexposed 20351 2471 (12.1) Reference Reference  Reference  
*2002, 2003, 2004, 2005, 2006, 2007, 2008 
† Delivery year, age, socioeconomic status, race, multiple pregnancy, parity, smoking status, alcohol or substance abuse during pregnancy, coagulation 
defects, asthma, diabetes, hypertension, previous caesarean section, and use of other psychotropic medications 
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Table 3. Relative risks (RR) and 95% confidence intervals (CI) comparing risk for severe primary postpartum haemorrhage (≥1000mL) 
according to exposure to antidepressants, psychiatric illness, or neither during pregnancy 
 Total No (%) of 
women with 
severe PPH 
Unadjusted Adjusted for delivery year* Fully Adjusted† 
   RR RR 95% CI RR 95% CI 
Any Type of Delivery        
Antidepressants 558 49 (8.8) 1.94 1.92 1.46, 2.52 1.84 1.39, 2.44 
Psychiatric Illness 1292 62 (4.8) 1.06 1.09 0.84, 1.40 1.10 0.85, 1.42 
Unexposed 28 348 1 283 (4.5) Reference Reference  Reference  
Caesarean Section        
Antidepressants 210 29 (13.8) 1.68 1.68 1.19, 2.37 1.70 1.20, 2.40 
Psychiatric Illness 391 34 (8.7) 1.06 1.08 0.78, 1.51 1.20 0.86, 1.67 
Unexposed 7 997 657 (8.2) Reference Reference  Reference  
Vaginal Delivery        
Antidepressants 348 20 (5.8) 1.87 1.83 1.19, 2.81 1.73 1.10, 2.73 
Psychiatric Illness 901 28 (3.1) 1.01 1.04 0.71, 1.53 0.98 0.66, 1.46 
Unexposed 20 351 626 (3.1) Reference Reference  Reference  
*2002, 2003, 2004, 2005, 2006, 2007, 2008 
† Delivery year, age, socioeconomic status, race, multiple pregnancy, parity, smoking status, alcohol or substance abuse during pregnancy, coagulation 
defects, asthma, diabetes, hypertension, previous caesarean section, and use of other psychotropic medications 
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Table 4. Relative risks (RR) and 95% confidence intervals (CI) comparing risk for postpartum anaemia according to exposure to 
antidepressants, psychiatric illness, or neither during pregnancy 




Unadjusted Adjusted for delivery year* Fully Adjusted† 
   RR RR 95% CI RR 95% CI 
Any Type of Delivery        
Antidepressants 558 83 (14.9) 1.82 1.81 1.48, 2.21 1.80 1.46, 2.22 
Psychiatric Illness 1292 105 (8.1) 0.99 1.01 0.83, 1.21 1.01 0.83, 1.22 
Unexposed 28 348 2322 (8.2) Reference Reference  Reference  
Caesarean Section        
Antidepressants 210 42 (20.0) 1.43 1.41 1.07, 1.87 1.44 1.07, 1.93 
Psychiatric Illness 391 55 (14.7) 1.01 1.04 0.80, 1.33 1.07 0.83, 1.39 
Unexposed 7997 1119 (14.0) Reference Reference  Reference  
Vaginal Delivery        
Antidepressants 348 41 (11.8) 1.99 1.99 1.49, 2.66 2.02 1.50, 2.73 
Psychiatric Illness 901 50 (5.6) 0.94 0.95 0.72, 1.25 0.91 0.68, 1.22 
Unexposed 20351 1203 (5.9) Reference Reference  Reference  
*2002, 2003, 2004, 2005, 2006, 2007, 2008 
† Delivery year, age, socioeconomic status, race, multiple pregnancy, parity, smoking status, alcohol or substance abuse during pregnancy, coagulation 
defects, asthma, diabetes, hypertension, previous caesarean section, and use of other psychotropic medications 
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Table S1. Prevalence of risk factors for postpartum haemorrhage according to exposure 
status among all women included in the study (N=30,198) 




N 558 1,292 28,348  
Primary PPH 91 (16) 139 (11) 3,128 (11) <0.001 
Severe PPH 49 (9) 62 (5) 1,283 (5) <0.001 
     
Tone     
Previous PPH 25 (4) 44 (3) 895 (3) 0.186 
Obesity 101 (27.3) 214 (23.8) 3,616 (18.6) <0.001 
Antenatal Anaemia 98 (18) 134 (10) 2,787 (10) <0.001 
Placenta Praevia 13 (2) 12 (1) 313 (1) 0.032 
Multiple Pregnancy 18 (3) 29 (2) 777 (3) 0.428 
Prolonged Labour 9 (2) 33 (3) 811 (3) 0.180 
Tissue     
Retained Placenta 15 (3) 17 (1) 457 (2) 0.105 
Manual removal of placenta 15 (3) 20 (2) 473 (2) 0.172 
Trauma     
Method of Delivery     
NVD 283 (51) 738 (57) 16,827 (59) <0.001 
Assisted Delivery 65 (12) 163 (13) 3,523 (12)  
Elective LSCS 85 (15) 142 (11) 2,792 (10)  
Emergency LSCS 125 (22) 249 (19) 5,206 (18)  
Macrosomia (>4,500g) 4 (<1) 16 (1) 458 (2) 0.160 
Thrombin     
Pyrexia in labour 8 (1) 24 (2) 465 (1) 0.777 
PIH 65 (12) 118 (9) 2,235 (8) 0.002 
Pre-existing thrombotic 
disorders 
6 (1) 6 (<1) 102 (<1) 0.035 
Abbreviations: PPH, postpartum haemorrhage; NVD, normal vaginal delivery; PIH, 
pregnancy induced hypertensive disorders 
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Table S2. Prevalence of risk factors for postpartum haemorrhage according to exposure 
status only among women with severe postpartum haemorrhage (N=1,394) 
 Antidepressant Psychiatric 
Illness 
Unexposed p-value 
Number 49 62 1,283  
Tone     
Previous PPH 3 (6.1) 6 (9.7) 83 (6.5) 0.582 
Obesity 7 (21.2) 17 (39.5) 219 (24.9) 0.101 
Antenatal Anaemia 13 (26.5) 6 (9.7) 161 (12.6) 0.020 
Placenta Praevia 6 (12.2) 5 (8.1) 106 (8.3) 0.513 
Multiple Pregnancy 3 (6.1) 3 (4.8) 71 (5.5) 0.943 
Prolonged Labour 0 6 (9.7) 58 (4.5) 0.059 
Tissue     
Retained Placenta 6 (12.2) 8 (12.9) 171 (13.3) 1.000 
Trauma     
Method of Delivery     
NVD 16 (32.7) 22 (35.5) 497 (38.7) 0.895 
Assisted Delivery 4 (8.2) 6 (9.7) 129 (10.0)  
Elective LSCS 7 (14.3) 9 (14.5) 199 (15.5)  
Emergency LSCS 22 (44.9) 25 (40.3) 458 (35.7)  
Macrosomia (>4,500g) 0 3 (4.8) 48 (3.7) 0.353 
Thrombin     
Pyrexia in labour 0 5 (8.1) 45 (3.5) 0.080 
PIH 7 (14.3) 11 (17.7) 131 (10.2) 0.117 
Pre-existing thrombotic 
disorders 
0 0 5 (0.4) 1.000 
Abbreviations: PPH, postpartum haemorrhage; NVD, normal vaginal delivery; PIH, 
pregnancy induced hypertensive disorders 
 
 
